PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

April 19, 2018Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma
April 11, 2018Notice of Annual General Meeting in Promore Pharma AB (publ)
February 15, 2018Promore Pharma Regains Rights for PXL01 Manufacturing
February 6, 2018Year-end report 2017

More Press Releases

Year-end report 2017

Year-end report 2017 was published on February 6, 2018.

Read the Report

Calendar

May 16, 2018Interim report January – March 2018
May 16, 2018Annual General Meeting 2018
June 4, 2018Redeye Growth Day

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

Promore Pharmas vision is to help patients with high medical needs in the area of bioactive wound care, through the development of products that strengthen and accelerate the body’s natural healing processes.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.